@article{d6693a977aae4927af4a5154f3fe3683,
title = "Evaluating the FDA regenerative medicine framework: Opportunities for stakeholders",
keywords = "FDA, drug regulation, laws, regenerative medicine, unproven stem cell interventions",
author = "Elizabeth Richardson and Farzana Akkas and Zubin Master",
note = "Funding Information: The authors thank the Pew Charitable Trusts for funding the original research on which this Commentary is based. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.",
year = "2020",
month = jul,
doi = "10.2217/rme-2020-0073",
language = "English (US)",
volume = "15",
pages = "1825--1832",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "7",
}